• 何玲

    药理系 教授
    领域:神经药理
    联系电话:
    电子邮箱:hexyz@163.com
    办公室:江宁校区学院实验楼504室
    实验室:江宁校区学院实验楼517
  • 1、教育经历
    (1) 1998/09-2002/06, 我校, 3499cc拉斯维加斯入口, 博士
    (2) 1992/09-1995/06, 我校, 3499cc拉斯维加斯入口, 硕士
    (3) 1988/09-1992/07, 我校, 3499cc拉斯维加斯入口, 学士
    2、工作经历
    (1)2009/06 至今, 我校, 3499cc拉斯维加斯入口, 教授
    (2)2004/05-2009/05,我校, 3499cc拉斯维加斯入口, 副教授
    (3)1995/08-2004.04,我校, 3499cc拉斯维加斯入口, 讲师
    3、学术荣誉
    2010/11,教育部新世纪优秀人才
    神经药理
    1、科研项目
    (1)国家自然科学基金委员会,面上项目,81673434,GPR40受体在阿尔茨海默症发病和治疗中的作用和机制研究,2017-01-01 至 2020-12-31,72.5 万元,已结题,主持
    (2) 国家科技部,“十二五”重大新药创制专项课题,2012ZX09504001-001,新型G蛋白偶联受体靶向药物筛选体系建立及其关键技术研究,2012-11-1至2016-12-31,332万元,已结题,主持。
    1.Wang, C.; Zheng, D.P.; Weng, F.L.; Jin, Y.Z.; He, L.* Sodium butyrate ameliorates the cognitive impairment of Alzheimer's disease by regulating the metabolism of astrocytes. Psychopharmacology (Berl). 2022;239(1),215-227. (IF: 4.415)
    2.Chen, T.; Liu, S.N.; Zheng, M.L; Li, Y.X.; He, L.* The effect of geniposide on chronic unpredictable mild stress-induced depressive mice through BTK/TLR4/NF-kappaB and BDNF/TrkB signaling pathways. Phytother Res. 2021;35(2),932-945. (IF: 5.878)
    3.Liu, C.; Cheng, Z.Y.; Xia, Q.P.; Hu, Y.H.; Wang, C.; He, L.* GPR40 receptor agonist TAK-875 improves cognitive deficits and reduces beta-amyloid production in APPswe/PS1dE9 mice. Psychopharmacology (Berl). 2021;238(8),2133-2146. (IF: 4.530)
    4.Gong, Y.; Li, Y.F.; Liu, X.; He, L.* GW9508 ameliorates cognitive dysfunction via the external treatment of encephalopathy in Abeta1-42 induced mouse model of Alzheimer's disease. Eur J Pharmacol. 2021;909,174362. (IF: 4.432)
    5.Cheng, Z.Y.; Hu, Y.H.; Xia, Q.P.; Wang, C.; He, L.* DRD1 agonist A-68930 improves mitochondrial dysfunction and cognitive deficits in a streptozotocin-induced mouse model. Brain Res Bull. 2021;175,136-149. (IF: 4.077)
    6.Zheng, M.L.; Li, K.; Chen, T.; Liu, S.N.; He, L.* Geniposide protects depression through BTK/JAK2/STAT1 signaling pathway in lipopolysaccharide-induced depressive mice. Brain Res Bull. 2021;170:65-73. (IF: 4.077)
    7.Wang, Y.; He, Y.; Yang, F.P.; Abame, M.A.; Wu, C.H.; Peng, Y.M.; Feng, L.Y.; Shen, J.S.; Wang, Z.*; He, L.* TPN672: A Novel Serotonin-Dopamine Receptor Modulator for the Treatment of Schizophrenia. J Pharmacol Exp Ther. 2021;378(1),20-30. (IF: 4.030)
    8.Gong, Y.H.; Chen, J.J.; Jin, Y.Z.; Wang, C.; Zheng, M.L.; He, L.* GW9508 ameliorates cognitive impairment via the cAMP-CREB and JNK pathways in APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuropharmacology. 2020;164,107899. (IF: 4.431)
    9.Cheng, Z.Y.; Xia, Q.P.; Hu, Y.H.; Wang, C.; He, L.* Dopamine D1 receptor agonist A-68930 ameliorates Aβ1-42-induced cognitive impairment and neuroinflammation in mice. Int Immunopharmacol. 2020;88:106963. (IF: 3.943)
    10.Chen, T.; Zheng, M.L.; Li, Y.X.; Liu, S.N.; He, L.* The role of CCR5 in the protective effect of Esculin on lipopolysaccharide-induced depressive symptom in mice.J Affect Disord. 2020;277:755-764. (IF: 3.892)
    研究团队 何玲教授,孙逸、陈同、邢孟韬 讲师,龚育杭 博士后
    Baidu
    sogou